✦ LIBER ✦

124 Activity and safety of the investigational agent orteronel (ortl, TAK-700) in men with nonmetastatic castration-resistant prostate cancer (CRPC) and rising prostate-specific antigen (PSA): Results of a phase 2 study

✍ Scribed by M. Hussain; P. Corn; D. Michaelson; H. Hammers; J. Alumkal; C. Ryan; J. Bruce; S. Moran; P. Mortimer; S.Y. Lee; D. George

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P115 A phase 2 multicenter study of the

✍ Hussain, M.; Corn, P.G.; Michaelson, D.; Hammers, H.J.; Alumkal, J.J.; Ryan, C.J 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 75 KB

P114 Safety and efficacy of orteronel (T

✍ Petrylak, D.; Gandhi, J.; Clark, W.R.; Heath, E.I.; Lin, J.; Oh, W.K.; Agus, D.B 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 61 KB